XOMA Royalty Confirms Merger Closing Date, Redeems $68.6M Preferred Stock, and Sets CVR Record Date
Summary
XOMA Royalty Corp announced the expected closing date for its acquisition by Ligand Pharmaceuticals, alongside the redemption of all preferred stock totaling $68.6 million and the record date for CVR distribution.
Key Events
-
Merger Closing Date Confirmed
The acquisition by Ligand Pharmaceuticals is now expected to close on or about July 14, 2026, providing a definitive timeline for the transaction.
-
Preferred Stock Redemption Announced
All outstanding Series A and Series B Cumulative Perpetual Preferred Stock will be redeemed on July 14, 2026, at $25.00 per share/depositary share, plus accrued dividends. This redemption totals approximately $68.6 million and is a key step for the merger.
-
CVR Record Date Set
A record date of July 13, 2026, has been set for the distribution of Contingent Value Rights (CVRs) to common stockholders, entitling them to potential future payments related to the Janssen Litigation.
Analysis
This filing provides critical updates on the pending acquisition by Ligand Pharmaceuticals. The company confirmed an expected closing date of July 14, 2026, which provides a firm timeline for the transaction. More importantly, XOMA Royalty announced the redemption of all outstanding Series A and Series B preferred stock, totaling approximately $68.6 million. This significant capital event is a necessary step to clear the balance sheet ahead of the merger. Additionally, setting the record date for Contingent Value Rights (CVRs) ensures common stockholders know their entitlement to potential future payments related to the Janssen Litigation.
At the time of this filing, XOMA was trading at $41.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $738.8M. The 52-week trading range was $22.29 to $42.81. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.